Ultimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting
May 10, 2022 02:00 ET
|
Ultimovacs ASA
UV1 immune monitoring data from three Phase I/IIa clinical trials show dynamic T cell responses lasting up to 7.5 yearsMeasurable UV1-specific immune response in 91% of patients when combined with...
Ultimovacs ASA: Invitation to first quarter 2022 results webcast presentation
May 05, 2022 02:00 ET
|
Ultimovacs ASA
Ultimovacs ASA: Invitation to first quarter 2022 results webcast presentation Oslo, 5 May 2022: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for...
Ultimovacs Receives Notice of Allowance on US Patent on Vaccine-Checkpoint Inhibitor Combinations
April 22, 2022 02:00 ET
|
Ultimovacs ASA
Extends protection for UV1 vaccine-checkpoint inhibitor combinations until at least 2037Covers UV1 with CTLA-4, PD-1 or PD-L1 checkpoint inhibitors Oslo, 22 April 2022: Ultimovacs ASA ("Ultimovacs")...
Ultimovacs ASA - Share Option Program
April 21, 2022 10:30 ET
|
Ultimovacs ASA
Oslo, 21 April 2022: On the basis of the approval by the General Meeting on 21 April 2022 to authorize the Board of Directors of Ultimovacs ASA (the ‘Company’, OSE ticker “ULTI”) to issue new shares...
Ultimovacs ASA – Annual General Meeting held on 21 April 2022
April 21, 2022 05:14 ET
|
Ultimovacs ASA
Oslo, 21 April 2022: Ultimovacs ASA held its annual general meeting today 21 April 2022. All the matters on the agenda were approved. All board members were re-elected for a period of one year,...
Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development
April 08, 2022 13:00 ET
|
Ultimovacs ASA
TET platform shows efficient T cell priming and beneficial safety profile Data supported clinical transition to ongoing TENDU Phase I trialTET platform offers potential to strengthen T cell response...
Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting
April 08, 2022 10:30 ET
|
Ultimovacs ASA
Oslo, 08 April 2022: In connection with the Annual General Meeting of Ultimovacs ASA to be held on 21 April 2022, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy based...
Ultimovacs to host Investor Days 2022: Meet the Team
March 30, 2022 05:00 ET
|
Ultimovacs ASA
Oslo, 30 March 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, will host Investor Days 2022: Meet the Team events in several cities....
Correction: Ultimovacs ASA: Annual Report 2021
March 25, 2022 03:47 ET
|
Ultimovacs ASA
Oslo, 25 March 2021: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces that the Board of Directors of Ultimovacs ASA has approved...
Ultimovacs ASA: Notice of Annual General Meeting on 21 April 2022
March 25, 2022 02:50 ET
|
Ultimovacs ASA
Oslo, 25 March 2022, the Board of Directors hereby calls for the Annual General Meeting of Ultimovacs ASA (the "Company") in the meeting room ‘Jónas Einarsson auditorium’ in Ullernchausséen 64, 0379...